B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

Oncology·MeSH: Leukemia, Biphenotypic, Acute

Prevalence

8.0 / 100K

Incidence

1.8 / 100K/yr

23 drugs in development·6 companies·5 clinical trials

Drug Pipeline by Phase

Phase 3(20)
DrugCompany
Bleomycin SulfateAXIM BIOTECHNOLOGIES, INC. (AXIM)
BlinatumomabAXIM BIOTECHNOLOGIES, INC. (AXIM)
BlinatumomabCrinetics Pharmaceuticals, Inc. (CRNX)
CytarabineAXIM BIOTECHNOLOGIES, INC. (AXIM)
CytarabineCrinetics Pharmaceuticals, Inc. (CRNX)
DasatinibCrinetics Pharmaceuticals, Inc. (CRNX)
DasatinibAXIM BIOTECHNOLOGIES, INC. (AXIM)
Daunorubicin HydrochlorideAXIM BIOTECHNOLOGIES, INC. (AXIM)
MesnaAssertio Holdings, Inc. (ASRT)
MesnaAXIM BIOTECHNOLOGIES, INC. (AXIM)
MesnaMerus N.V. (MRUS)
MesnaCrinetics Pharmaceuticals, Inc. (CRNX)
PonatinibENANTA PHARMACEUTICALS INC (ENTA)
Ponatinib HydrochlorideCrinetics Pharmaceuticals, Inc. (CRNX)
Ponatinib HydrochlorideAXIM BIOTECHNOLOGIES, INC. (AXIM)
Procarbazine HydrochlorideAXIM BIOTECHNOLOGIES, INC. (AXIM)
Vinblastine SulfateAXIM BIOTECHNOLOGIES, INC. (AXIM)
VincristineAXIM BIOTECHNOLOGIES, INC. (AXIM)
Vincristine SulfateCrinetics Pharmaceuticals, Inc. (CRNX)
Vincristine SulfateAXIM BIOTECHNOLOGIES, INC. (AXIM)

Compare drugs

Bleomycin Sulfate vs BlinatumomabBleomycin Sulfate vs CytarabineBleomycin Sulfate vs Dasatinib

Frequently asked questions

How many drugs are in development for B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1?

BioSniper tracks 23 drugs in development for B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 across 6 companies.

How many clinical trials target B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1?

There are 5 clinical trials targeting B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 tracked by BioSniper.

What is the prevalence of B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1?

The estimated prevalence of B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 is approximately 8.0 per 100,000 population.

Deep-dive into B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 — Drugs in Development & Clinical Trials | BioSniper